178 related articles for article (PubMed ID: 16794364)
1. Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.
Chang TC; Liao SL
J Endocrinol Invest; 2006 May; 29(5):413-22. PubMed ID: 16794364
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.
Stan MN; Garrity JA; Bradley EA; Woog JJ; Bahn MM; Brennan MD; Bryant SC; Achenbach SJ; Bahn RS
J Clin Endocrinol Metab; 2006 Dec; 91(12):4817-24. PubMed ID: 16984988
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
5. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
6. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.
Wémeau JL; Caron P; Beckers A; Rohmer V; Orgiazzi J; Borson-Chazot F; Nocaudie M; Perimenis P; Bisot-Locard S; Bourdeix I; Dejager S
J Clin Endocrinol Metab; 2005 Feb; 90(2):841-8. PubMed ID: 15562016
[TBL] [Abstract][Full Text] [Related]
7. Three dimensional orbital magnetic resonance T2-mapping in the evaluation of patients with Graves' ophthalmopathy.
Hou K; Ai T; Hu WK; Luo B; Wu YP; Liu R
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):938-942. PubMed ID: 29270757
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Fisher GA; Wolin EM; Liyanage N; Pitman Lowenthal S; Mirakhur B; Pommier RF; Shaheen M; Vinik A;
Oncologist; 2018 Jan; 23(1):16-24. PubMed ID: 29038234
[TBL] [Abstract][Full Text] [Related]
9. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
Caron P; Morange-Ramos I; Cogne M; Jaquet P
J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
[TBL] [Abstract][Full Text] [Related]
10. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.
Dickinson AJ; Vaidya B; Miller M; Coulthard A; Perros P; Baister E; Andrews CD; Hesse L; Heverhagen JT; Heufelder AE; Kendall-Taylor P
J Clin Endocrinol Metab; 2004 Dec; 89(12):5910-5. PubMed ID: 15579735
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
13. [Lanreotide in the treatment of thyroid orbitopathy].
Pilarska K; Kulig G
Przegl Lek; 2004; 61(8):845-7. PubMed ID: 15789913
[TBL] [Abstract][Full Text] [Related]
14. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.
Krassas GE; Gogakos A
J Pediatr Endocrinol Metab; 2006 Oct; 19(10):1193-206. PubMed ID: 17172081
[TBL] [Abstract][Full Text] [Related]
15. Lanreotide Autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial.
Gauthier T; Garuchet-Bigot A; Marin B; Mollard J; Loum O; Fermeaux V; Jammet I; Kanoun D; Maubon A; Aubard Y
Eur J Surg Oncol; 2012 Oct; 38(10):902-9. PubMed ID: 22703757
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.
Mariani P; Blumberg J; Landau A; Lebrun-Jezekova D; Botton E; Beatrix O; Mayeur D; Herve R; Maisonobe P; Chauvenet L
J Clin Oncol; 2012 Dec; 30(35):4337-43. PubMed ID: 23109694
[TBL] [Abstract][Full Text] [Related]
17. Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy.
Su DH; Chang YC; Liao SL; Chang TC
Graefes Arch Clin Exp Ophthalmol; 2005 Mar; 243(3):269-72. PubMed ID: 15452720
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of rituximab in patients with Graves' orbitopathy.
Stan MN; Garrity JA; Carranza Leon BG; Prabin T; Bradley EA; Bahn RS
J Clin Endocrinol Metab; 2015 Feb; 100(2):432-41. PubMed ID: 25343233
[TBL] [Abstract][Full Text] [Related]
19. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
[TBL] [Abstract][Full Text] [Related]
20. A Prospective, Randomized, Double-blind, Placebo-controlled Study of Orbital Radiotherapy for Graves' Ophthalmopathy.
Gorman CA; Garrity JA; Fatourechi V; Bahn RS; Petersen IA; Stafford SL; Earle JD; Forbes GS; Kline RW; Bergstralh EJ; Offord KP; Rademacher DM; Stanley NM; Bartley GB
Ophthalmology; 2020 Apr; 127(4S):S160-S171. PubMed ID: 32200817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
